refractory lymphoma
Showing 1 - 25 of 34
Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma Trial in Boston (Adaptive Bridging Radiation Therapy (ABRT))
Not yet recruiting
- Lymphoma, B-Cell
- +7 more
- Adaptive Bridging Radiation Therapy (ABRT)
-
Boston, MassachusettsDana-Farber Cancer Institute
Aug 16, 2023
SALVAGE TREATMENT WITH GLOFITAMAB IN RELAPSED/REFRACTORY B-NHL:
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- +2 more
- (no location specified)
Jun 22, 2023
Brain Stem Tumor, Pineal Region Tumor, Recurrent Lymphoma Trial in United States (Entinostat, Laboratory Biomarker Analysis,
Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma, Recurrent Lymphoma Trial in United States (Elimusertib)
Recruiting
- Recurrent Alveolar Rhabdomyosarcoma
- +7 more
-
Birmingham, Alabama
- +28 more
Jan 26, 2023
T-lymphoblastic Lymphoma, Relapsed Disease, Refractory Lymphoma Trial in Shanghai (BCL2 Inhibitor plus IM2 regimen)
Recruiting
- T-lymphoblastic Lymphoma
- +5 more
- BCL2 Inhibitor plus IM2 regimen
-
Shanghai, Shanghai, ChinaShanghai General hospital,Shanghai Jiao Tong University School o
Jan 10, 2023
Recurrent DLBCL Germinal Center B-Cell Type, Recurrent Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma Trial (Belinostat,
Not yet recruiting
- Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
- +5 more
- Belinostat
- +2 more
- (no location specified)
Dec 2, 2022
Recurrent Lymphoma, Recurrent Malignant Solid Tumor, Recurrent Primary CNS Tumor Trial in United States (Irinotecan,
Active, not recruiting
- Recurrent Lymphoma
- +5 more
- Irinotecan
- +2 more
-
Birmingham, Alabama
- +19 more
Oct 20, 2022
Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Tumor, Lynch Syndrome Trial in Canada,
Withdrawn
- Constitutional Mismatch Repair Deficiency Syndrome
- +11 more
- Biospecimen Collection
- +2 more
-
Palo Alto, California
- +8 more
Sep 9, 2022
Hematopoietic and Lymphoid Cell Tumor, Recurrent Ependymoma, Recurrent Ewing Sarcoma Trial in Puerto Rico, United States
Recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +37 more
-
Birmingham, Alabama
- +171 more
Aug 24, 2022
Advanced Malignant Solid Tumor, Bladder Carcinoma, Breast Carcinoma Trial in Guam, Puerto Rico, United States (drug, procedure,
Recruiting
- Advanced Malignant Solid Neoplasm
- +49 more
- Adavosertib
- +36 more
-
Birmingham, Alabama
- +1429 more
Aug 17, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Trametinib
Active, not recruiting
- Advanced Lymphoma
- +5 more
- Trametinib Dimethyl Sulfoxide
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Aug 13, 2022
Mantle Cell Lymphoma, Refractory Lymphoma Trial in Boston (Acalabrutinib, Venetoclax, Obinutuzumab)
Recruiting
- Mantle Cell Lymphoma
- Refractory Lymphoma
- Acalabrutinib
- +2 more
-
Boston, Massachusetts
- +1 more
Aug 8, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid System Tumor Trial in Philadelphia (Biopsy,
Active, not recruiting
- Advanced Lymphoma
- +5 more
- Biopsy
- +3 more
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Aug 5, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Capivasertib)
Active, not recruiting
- Advanced Lymphoma
- +5 more
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Jun 28, 2022
Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Malignant Tumor in the CNS, Recurrent Diffuse Intrinsic Pontine Glioma Trial
Active, not recruiting
- Diffuse Midline Glioma, H3 K27M-Mutant
- +10 more
- FACT Complex-targeting Curaxin CBL0137
-
Birmingham, Alabama
- +19 more
Jun 29, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Advanced Pancreatic Carcinoma Trial in New Haven (BET Bromodomain Inhibitor
Recruiting
- Advanced Lymphoma
- +13 more
- BET Bromodomain Inhibitor ZEN-3694
- +2 more
-
New Haven, ConnecticutYale University Cancer Center LAO
Jun 29, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Afatinib
Active, not recruiting
- Advanced Lymphoma
- +5 more
- Afatinib Dimaleate
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Jun 28, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Defactinib
Active, not recruiting
- Advanced Lymphoma
- +5 more
- Defactinib Hydrochloride
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Jun 28, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Adavosertib)
Active, not recruiting
- Advanced Lymphoma
- +5 more
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Jun 28, 2022
Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent
Recruiting
- Clonal Cytopenia of Undetermined Significance
- +6 more
- Ascorbic Acid
- +12 more
-
Scottsdale, Arizona
- +4 more
May 26, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Taselisib)
Active, not recruiting
- Advanced Lymphoma
- +5 more
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Feb 4, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Crizotinib)
Active, not recruiting
- Advanced Lymphoma
- +5 more
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Feb 4, 2022
Solving Riddles Through Sequencing
Recruiting
- Leukemia
- +5 more
- Next Generation Sequencing
-
Munich, GermanyMLL Munich Leukemia Laboratory
Jan 19, 2022
Polatuzumab Vedotin in Relapsed and Refractory Diffuse Large B
Completed
- Relapsed Non Hodgkin Lymphoma
- Refractory Lymphoma
-
Taipei, TaiwanNational Taiwan University Hospital
Aug 8, 2021
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (FGFR Inhibitor
Completed
- Advanced Lymphoma
- +5 more
- FGFR Inhibitor AZD4547
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Jun 8, 2021